Platforms

Platforms across the development lifecycle. One stack.

Atlas Bio builds prediction, validation, and decision tools that span the full drug development pipeline — in-silico discovery and the wet-lab loop through post-market evidence. Every tool runs on the same underlying stack: a shared evidence pipeline, a common audit layer, and a single validation standard. So a result produced for one program is directly comparable to a result produced for any other.

Lifecycle map

For each phase of the full pipeline — from in-silico discovery through post-market surveillance — we map the Atlas Bio platform tools that serve it and the Atlas Bio pipeline studies currently at that phase. The five phases pose five different questions — which molecule is worth making (P1), will it translate to humans (P2), is it safe and effective (P3), is the evidence submission-ready (P4), is the post-market signal holding (P5) — and each tool is purpose-built for the question its phase asks.

P1 · Discovery & Optimization

Candidate generation

In-silico screen → wet-lab loop.
Atlas Bio tools
Pipeline studies (target & compound design)
P2 · Research & Translation

Translation probability

Will this candidate work in humans?
Atlas Bio tools
Pipeline studies (mechanism design)
P3 · Clinical Trials

Safety → efficacy → readout

Phase I dose safety · Phase II signal · Phase III outcome.
Atlas Bio tools
Pipeline studies (6 active)
P4 · Regulatory & Ops

Submission readiness

Is the evidence package audit-ready?
Atlas Bio tools
Pipeline studies
  • Regulatory dossiers assemble once a program clears its pre-registered Phase III readout.
P5 · Commercial & Post-Market

RWE drift detection

Is the real-world signal holding?
Atlas Bio tools
Pipeline studies
  • Post-market monitoring applies once a program reaches approval.

Which platform fits your question?

Briefings start with a 30-minute scope call. We'll tell you which platform applies (or whether the question is out-of-scope).

Contact Us →